Search results
Results From The WOW.Com Content Network
The analyst also highlights that the sale of Edwards’ Critical Care business to Becton, Dickinson and Company in September 2024 could positively impact Edwards' valuation.
(Reuters) -Edwards Lifesciences on Monday said it has agreed to sell its critical care products unit to Becton Dickinson in an all-cash deal valued at $4.2 billion to sharpen focus on its heart ...
Investors are optimistic about Edwards Lifesciences (EW) on continued strong adoption of the SAPIEN 3 Ultra platform and the PASCAL system.
For premium support please call: 800-290-4726 more ways to reach us
On Wednesday, during its annual investor conference, Edwards Lifesciences Corporation (NYSE:EW) detailed its strategy for sustained long-term growth and innovations in structural heart therapies.
The company was founded in 1897 in New York City by Maxwell Becton and Fairleigh S. Dickinson.It later moved its headquarters to New Jersey. In 2004, BD agreed to pay out US$100 million to settle allegations from competitor Retractable Technologies that it had engaged in anti-competitive behavior to prevent the distribution of Retractable's syringes, which are designed to prevent needlestick ...
The stock of Edwards Lifesciences (NYSE:EW, 30-year Financials) gives every indication of being modestly overvalued, according to GuruFocus Value calculation.
Investor confidence is high in Edwards Lifesciences (EW) stock, courtesy of solid prospects.